All news

William Blair cuts Moderna to Market Perform on valuation

Alpha Vantage · Investing.com · · AI-summarised by FinFlash

Moderna shares fell in premarket trading after William Blair downgraded the stock to Market Perform from Outperform, citing valuation after a 545% year-to-date rally. Analysts said the current valuation already reflects an aggressive probability of success across expanded oncology indications. Investor focus is shifting to the commercial boundaries of intismeran and upcoming trial readouts.

Read original source

MRNA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.